Pfizer’s Ibrance (palbociclib) won FDA approval on June 24, 2026, for maintenance treatment of adults with hormone receptor-positive, HER2-positive metastatic breast cancer, marking the first time a CDK4/6 inhibitor has been approved for this patient population regardless of HER2 status.
The approval is based on data from the Phase 3 PATINA trial, which demonstrated a 24% reduction in the risk of progression or death when palbociclib was added to standard anti-HER2 therapy and endocrine therapy after initial induction treatment. The trial showed progression-free survival reached 44 months with palbociclib added to maintenance therapy, compared with 29 months for standard care alone—a 15-month improvement, according to Pfizer’s announcement.
Ibrance is indicated for use in combination with trastuzumab, with or without pertuzumab, and endocrine therapy. The approval expands the drug’s reach beyond its established role in HR-positive, HER2-negative metastatic breast cancer, a distinction it has held since its initial FDA approval in 2015 as the first CDK4/6 inhibitor in the class. Prior to this approval, CDK4/6 inhibitors had been approved only for HR-positive, HER2-negative disease, leaving the HR+/HER2+ population without a CDK4/6 option.
HR-positive, HER2-positive metastatic breast cancer represents a distinct patient segment often treated with anti-HER2 drugs like trastuzumab in combination with hormonal therapy. The PATINA trial data suggest that adding a CDK4/6 inhibitor to this regimen can delay disease progression. The trial enrolled patients with locally advanced or metastatic HR+/HER2+ breast cancer who had received induction therapy with trastuzumab-based chemotherapy, then randomly assigned them to receive either maintenance anti-HER2 and endocrine therapy alone or with palbociclib added.
Analysts noted that this approval opens access to an underserved segment of the breast cancer population. The timing comes as Ibrance faces patent expiration in the United States in 2027, potentially limiting the commercial window for this new indication. Still, the expansion broadens Ibrance’s clinical utility and reinforces its role in Pfizer’s oncology portfolio at a critical juncture.
Sources
- Pfizer — FDA approval announcement and PATINA trial efficacy data (24% risk reduction, 15-month PFS improvement)
- FDA — Official approval notification for palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy
- AJMC (American Journal of Managed Care) — Confirmation of trial data and approval details
- FirstWord Pharma — Trial efficacy details and clinical context
- Simply Wall Street — Market significance and underserved population context
